Cargando…

Clash of the calculators: External validation of prostate cancer risk calculators in men undergoing mpMRI and transperineal biopsy

OBJECTIVE: To compare the accuracy of the European Randomized Study of Screening for Prostate Cancer (ERSPC) RC, MRI‐ERSPC‐RC, and Prostate Biopsy Collaborative Group (PBCG) RC in patients undergoing transperineal prostate biopsy. PATIENTS AND METHODS: We identified 392 patients who underwent mpMRI...

Descripción completa

Detalles Bibliográficos
Autores principales: Wei, G., Kelly, B. D., Timm, B., Perera, M., Lundon, D. J., Jack, G., Bolton, D. M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8988740/
https://www.ncbi.nlm.nih.gov/pubmed/35475133
http://dx.doi.org/10.1002/bco2.58
_version_ 1784683030615425024
author Wei, G.
Kelly, B. D.
Timm, B.
Perera, M.
Lundon, D. J.
Jack, G.
Bolton, D. M.
author_facet Wei, G.
Kelly, B. D.
Timm, B.
Perera, M.
Lundon, D. J.
Jack, G.
Bolton, D. M.
author_sort Wei, G.
collection PubMed
description OBJECTIVE: To compare the accuracy of the European Randomized Study of Screening for Prostate Cancer (ERSPC) RC, MRI‐ERSPC‐RC, and Prostate Biopsy Collaborative Group (PBCG) RC in patients undergoing transperineal prostate biopsy. PATIENTS AND METHODS: We identified 392 patients who underwent mpMRI before transperineal prostate biopsy across multiple public and private institutions between January 2017 and August 2019. The estimated probabilities of detecting PCa and significant PCa were calculated using the MRI‐ERSPC‐RC, ERSPC‐RC, and PBCG‐RC. Receiver operating characteristic (ROC) curves for each calculator were generated and the area underneath the curve (AUC) was compared. Calibration and clinical utility were assessed with calibration plots and decision curve analysis, respectively. RESULTS: PCa was detected in 285 patients (72.7%) with significant PCa found in 200 patients (51.1%). ROC curve analysis found the MRI‐ERSPC‐RC outperformed the ERSPC‐RC and PBCG‐RC. For the prediction of PCa, the AUC was 0.756, 0.696, and 0.675 for the MRI‐ERSPC‐RC, ERSPC‐RC, and PBCG‐RC, respectively. The AUC for the prediction of significant PCa was 0.803, 0.745, and 0.746 for the MRI‐ERSPC‐RC, ERSPC‐RC, and PBCG‐RC, respectively. CONCLUSIONS: Our study validated the ERSPC‐RC, MRI‐ERSPC‐RC, and PBCG‐RC in a cohort undergoing transperineal prostate biopsy with the MRI‐ERSPC‐RC performing the best. These RCs may enable improved shared decision making and help to guide patient selection for biopsy.
format Online
Article
Text
id pubmed-8988740
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-89887402022-04-25 Clash of the calculators: External validation of prostate cancer risk calculators in men undergoing mpMRI and transperineal biopsy Wei, G. Kelly, B. D. Timm, B. Perera, M. Lundon, D. J. Jack, G. Bolton, D. M. BJUI Compass Original Articles OBJECTIVE: To compare the accuracy of the European Randomized Study of Screening for Prostate Cancer (ERSPC) RC, MRI‐ERSPC‐RC, and Prostate Biopsy Collaborative Group (PBCG) RC in patients undergoing transperineal prostate biopsy. PATIENTS AND METHODS: We identified 392 patients who underwent mpMRI before transperineal prostate biopsy across multiple public and private institutions between January 2017 and August 2019. The estimated probabilities of detecting PCa and significant PCa were calculated using the MRI‐ERSPC‐RC, ERSPC‐RC, and PBCG‐RC. Receiver operating characteristic (ROC) curves for each calculator were generated and the area underneath the curve (AUC) was compared. Calibration and clinical utility were assessed with calibration plots and decision curve analysis, respectively. RESULTS: PCa was detected in 285 patients (72.7%) with significant PCa found in 200 patients (51.1%). ROC curve analysis found the MRI‐ERSPC‐RC outperformed the ERSPC‐RC and PBCG‐RC. For the prediction of PCa, the AUC was 0.756, 0.696, and 0.675 for the MRI‐ERSPC‐RC, ERSPC‐RC, and PBCG‐RC, respectively. The AUC for the prediction of significant PCa was 0.803, 0.745, and 0.746 for the MRI‐ERSPC‐RC, ERSPC‐RC, and PBCG‐RC, respectively. CONCLUSIONS: Our study validated the ERSPC‐RC, MRI‐ERSPC‐RC, and PBCG‐RC in a cohort undergoing transperineal prostate biopsy with the MRI‐ERSPC‐RC performing the best. These RCs may enable improved shared decision making and help to guide patient selection for biopsy. John Wiley and Sons Inc. 2021-03-03 /pmc/articles/PMC8988740/ /pubmed/35475133 http://dx.doi.org/10.1002/bco2.58 Text en © 2021 The Authors. BJUI Compass published by John Wiley & Sons Ltd on behalf of BJU International Company https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Articles
Wei, G.
Kelly, B. D.
Timm, B.
Perera, M.
Lundon, D. J.
Jack, G.
Bolton, D. M.
Clash of the calculators: External validation of prostate cancer risk calculators in men undergoing mpMRI and transperineal biopsy
title Clash of the calculators: External validation of prostate cancer risk calculators in men undergoing mpMRI and transperineal biopsy
title_full Clash of the calculators: External validation of prostate cancer risk calculators in men undergoing mpMRI and transperineal biopsy
title_fullStr Clash of the calculators: External validation of prostate cancer risk calculators in men undergoing mpMRI and transperineal biopsy
title_full_unstemmed Clash of the calculators: External validation of prostate cancer risk calculators in men undergoing mpMRI and transperineal biopsy
title_short Clash of the calculators: External validation of prostate cancer risk calculators in men undergoing mpMRI and transperineal biopsy
title_sort clash of the calculators: external validation of prostate cancer risk calculators in men undergoing mpmri and transperineal biopsy
topic Original Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8988740/
https://www.ncbi.nlm.nih.gov/pubmed/35475133
http://dx.doi.org/10.1002/bco2.58
work_keys_str_mv AT weig clashofthecalculatorsexternalvalidationofprostatecancerriskcalculatorsinmenundergoingmpmriandtransperinealbiopsy
AT kellybd clashofthecalculatorsexternalvalidationofprostatecancerriskcalculatorsinmenundergoingmpmriandtransperinealbiopsy
AT timmb clashofthecalculatorsexternalvalidationofprostatecancerriskcalculatorsinmenundergoingmpmriandtransperinealbiopsy
AT pereram clashofthecalculatorsexternalvalidationofprostatecancerriskcalculatorsinmenundergoingmpmriandtransperinealbiopsy
AT lundondj clashofthecalculatorsexternalvalidationofprostatecancerriskcalculatorsinmenundergoingmpmriandtransperinealbiopsy
AT jackg clashofthecalculatorsexternalvalidationofprostatecancerriskcalculatorsinmenundergoingmpmriandtransperinealbiopsy
AT boltondm clashofthecalculatorsexternalvalidationofprostatecancerriskcalculatorsinmenundergoingmpmriandtransperinealbiopsy